Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Bacteroides cocktail
- Development stage
- Unknown
- Lead developer
- Baylor College of Medicine
- Modality
- Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics
- Administration
- Oral, Rectal
01
Overview
The Bacteroides cocktail is a defined microbial consortium developed by researchers at Baylor College of Medicine for the treatment of recurrent *Clostridium difficile* infection (CDI). Unlike traditional fecal microbiota transplantation (FMT), which utilizes screened donor stool, this "defined FMT" consists of a standardized mixture of specific commensal bacterial strains, primarily from the *Bacteroides* genus. The cocktail typically includes six strains: *Bacteroides ovatus*, *Bacteroides thetaiotaomicron*, *Bacteroides vulgatus*, *Bacteroides fragilis*, *Bacteroides distasonis* (now *Parabacteroides distasonis*), and *Bacteroides uniformis*. The therapy is designed to restore the ecological balance of the intestinal microbiota and re-establish colonization resistance against *C. difficile* by competing for nutrients and producing inhibitory metabolites. It was evaluated in a Phase 1 clinical trial specifically targeting the Veteran Affairs (VA) patient population suffering from recurrent CDI.
- Other names
- Defined FMTDefined Fecal Microbiota TransplantBaylor Bacteroides cocktailDefined microbial consortium
Beyond the preview
Go deeper on Bacteroides cocktail.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Bacteroides cocktail.